AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35323121 — intervention group
Group type: EXPERIMENTAL
Intervention: SurgeCon intervention (protocol-driven software platform, restructured ED organization and workflow)
Number of subjects: 570
Study 35323121 — intervention group
Group type: EXPERIMENTAL
Intervention: SurgeCon intervention
Number of subjects: 570
Study 35323125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Decision Support System (DDSS) prototype
Number of subjects: 20
Study 35323379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST) with intranasal oxytocin
Number of subjects: 0
Study 35323379 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Social Skills Training (CBSST) with placebo
Number of subjects: 0
Study 35323885 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (oral and written education about LB)
Number of subjects: 196
Study 35323885 — intervention group
Group type: COMPARATOR
Intervention: Control group (remaining general practices in Funen)
Number of subjects: 196
Study 35323895 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus early-onset disease (GBS EOD)
Number of subjects: 0
Study 35323895 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B Streptococcus late-onset disease (GBS LOD)
Number of subjects: 0
Study 35323895 — intervention group
Group type: COMPARATOR
Intervention: Other infections
Number of subjects: 0
Study 35323895 — intervention group
Group type: COMPARATOR
Intervention: Uninfected infants
Number of subjects: 0
Study 35323905 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral dydrogesterone (DYD) ter-in-die (tid) for luteal support
Number of subjects: 217
Study 35323932 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction model containing Neutrophil-to-lymphocyte ratio (NLR)
Number of subjects: 426
Study 35323932 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction model containing soluble urokinase plasminogen activator receptor (suPAR)
Number of subjects: 426
Study 35323932 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction model containing interleukin 6 (IL-6)
Number of subjects: 426
Study 35323932 — intervention group
Group type: COMPARATOR
Intervention: Clinical parameters alone (without biomarkers)
Number of subjects: 426
Study 35324081 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence (≥80% adherence)
Number of subjects: 37
Study 35324081 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP adherence (<80% adherence)
Number of subjects: 37
Study 35324081 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP uptake
Number of subjects: 37
Study 35324081 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP effectiveness confidence
Number of subjects: 37
Study 35324081 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-level dynamics
Number of subjects: 37
Study 35324081 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-level support
Number of subjects: 37
Study 35324095 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 0
Study 35324095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antipsychotic treatment)
Number of subjects: 0
Study 35324429 — intervention group
Group type: EXPERIMENTAL
Intervention: ASE algorithm for assessing MR severity
Number of subjects: 152
Study 35324429 — intervention group
Group type: EXPERIMENTAL
Intervention: Post mitral intervention LV reverse remodeling
Number of subjects: 152
Study 35324429 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe MR by CMR
Number of subjects: 152
Study 35324429 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitely severe MR by ASE algorithm
Number of subjects: 152
Study 35324532 — intervention group
Group type: EXPERIMENTAL
Intervention: selpercatinib plus crizotinib
Number of subjects: 1
Study 35324532 — intervention group
Group type: EXPERIMENTAL
Intervention: selpercatinib
Number of subjects: 1
Study 35324532 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab combined with pemetrexed and carboplatin
Number of subjects: 1
Study 35324894 — intervention group
Group type: COMPARATOR
Intervention: Total artificial sweeteners (above median exposure in consumers)
Number of subjects: 102865
Study 35324894 — intervention group
Group type: COMPARATOR
Intervention: Aspartame
Number of subjects: 102865
Study 35324894 — intervention group
Group type: COMPARATOR
Intervention: Acesulfame-K
Number of subjects: 102865
Study 35324894 — intervention group
Group type: COMPARATOR
Intervention: Total artificial sweeteners
Number of subjects: 102865
Study 35325189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined or separate measures of food reward or biometric responses
Number of subjects: 100
Study 35325189 — intervention group
Group type: COMPARATOR
Intervention: Naïve model (linear model including only an intercept)
Number of subjects: 100
Study 35325189 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake from an ad libitum buffet of 8 foods
Number of subjects: 100
Study 35325195 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic semi-conducting (OSC) sensors
Number of subjects: 3921
Study 35325195 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained dogs
Number of subjects: 3921
Study 35325195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dog screening plus confirmatory PCR test
Number of subjects: 3921
Study 35325211 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-74699157 (100 mg)
Number of subjects: 10
Study 35325211 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-74699157 (200 mg)
Number of subjects: 10
Study 35325225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (MTD 24 mg) with capecitabine-based chemoradiation
Number of subjects: 20
Study 35325225 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based protein biomarkers (TSP-2, VEGF-R3, VEGF)
Number of subjects: 20
Study 35326718 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields/sorafenib (150 kHz for ≥18 h/day with sorafenib 400 mg BID)
Number of subjects: 27
Study 35327522 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 538
Study 35327522 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 538
Study 35327546 — intervention group
Group type: EXPERIMENTAL
Intervention: Acylcarnitine levels in patients with acute coronary syndrome
Number of subjects: 958
Study 35327546 — intervention group
Group type: EXPERIMENTAL
Intervention: C5 levels in unstable angina
Number of subjects: 958
Study 35327546 — intervention group
Group type: EXPERIMENTAL
Intervention: C10, C16, C18:1 and C18:2 levels in stable angina
Number of subjects: 958
Study 35327546 — intervention group
Group type: EXPERIMENTAL
Intervention: C2, C3, C4 and C8 levels in patients with diabetes mellitus
Number of subjects: 958
Study 35327546 — intervention group
Group type: EXPERIMENTAL
Intervention: C2, C4, C5 and C6 levels in patients with heavier calcification and lower left ventricular ejection fraction (LVEF)
Number of subjects: 958
Study 35327546 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 and C5 levels in high CAD complexity group (SYNTAX Score > 22)
Number of subjects: 958
Study 35327768 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher oxygen saturation targets
Number of subjects: 0
Study 35327768 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygen saturation targets
Number of subjects: 0
Study 35328299 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld diagnostic devices (tympanic thermometer, pulse oximeter, hemoglobinometer, glucometer)
Number of subjects: 0
Study 35328299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximeter
Number of subjects: 0
Study 35328299 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld diagnostic devices
Number of subjects: 0
Study 35328847 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu SensDx device testing
Number of subjects: 150
Study 35328847 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccination
Number of subjects: 150
Study 35329987 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior segment optical coherence tomography angiography (AS-OCTA)
Number of subjects: 46
Study 35329987 — intervention group
Group type: COMPARATOR
Intervention: AS-OCTA
Number of subjects: 46
Study 35330570 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-message notifications
Number of subjects: 0
Study 35330925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid volume reduction
Number of subjects: 0
Study 35330925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid, electrolyte, energy and nitrogen intake, fluid loss, estimated glomerular filtration rate (eGFR), and estimated plasma osmolality (eOSM) measurements
Number of subjects: 0
Study 35331039 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpharmacological health-related behaviors adherence
Number of subjects: 0
Study 35331304 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital POCUS with remote real-time supervision
Number of subjects: 24
Study 35331304 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote real-time supervision
Number of subjects: 24
Study 35331304 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical feasibility and quality of communication and live stream
Number of subjects: 24
Study 35331323 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pressure swings measurement during non-invasive respiratory support (NRS)
Number of subjects: 61
Study 35331323 — intervention group
Group type: COMPARATOR
Intervention: Esophageal pressure swings measurement
Number of subjects: 61
Study 35331335 — intervention group
Group type: EXPERIMENTAL
Intervention: ITNK cells
Number of subjects: 0
Study 35331335 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-ITNK cells
Number of subjects: 0
Study 35331335 — intervention group
Group type: EXPERIMENTAL
Intervention: sgBCL11B T cells
Number of subjects: 0
Study 35331419 — intervention group
Group type: EXPERIMENTAL
Intervention: Resmetirom (MGL-3196)
Number of subjects: 0
Study 35331419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35331503 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 120
Study 35331503 — intervention group
Group type: COMPARATOR
Intervention: Usual nutrition
Number of subjects: 120
Study 35331504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-focused quality improvement program (QIP) including education on macro- and micronutrient intake and physical exercise, dietary counseling, and provision of oral nutritional supplements (ONS) for daily intake over 60 days.
Number of subjects: 677
Study 35331504 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition-focused quality improvement program (QIP)
Number of subjects: 677
Study 35331634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks
Number of subjects: 8
Study 35331637 — intervention group
Group type: EXPERIMENTAL
Intervention: iVAC2L mechanical circulatory support (MCS)
Number of subjects: 29
Study 35332036 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose radiation (radiosurgery) targeting the retroperitoneal coeliac plexus nerve bundle with a single fraction of 25 Gy
Number of subjects: 120
Study 35332048 — intervention group
Group type: EXPERIMENTAL
Intervention: AFCA
Number of subjects: 2999
Study 35332048 — intervention group
Group type: EXPERIMENTAL
Intervention: AAD
Number of subjects: 2999
Study 35332048 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat procedure after AAD use
Number of subjects: 2999
Study 35332134 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant (escitalopram 20 mg/day)
Number of subjects: 66
Study 35332134 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant plus COX-2 inhibitor (celecoxib)
Number of subjects: 66
Study 35332134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35332134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid analysis for IL-1β
Number of subjects: 66
Study 35332278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) therapy, median 4.0 cycles (range, 1-20)
Number of subjects: 248
Study 35332278 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) therapy
Number of subjects: 248
Study 35332289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab therapy
Number of subjects: 29
Study 35332298 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement blockade
Number of subjects: 0
Study 35332298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35332334 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of COVID-19 vaccine
Number of subjects: 457
Study 35332334 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of COVID-19 vaccine
Number of subjects: 457
Study 35332334 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of COVID-19 vaccine
Number of subjects: 457
Study 35332334 — intervention group
Group type: COMPARATOR
Intervention: Full vaccination (two doses)
Number of subjects: 457
Study 35332426 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intraventricular ICP monitoring
Number of subjects: 18
Study 35332426 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ICP monitor (ICPni)
Number of subjects: 18
Study 35333095 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency, low-tidal-volume mechanical ventilation
Number of subjects: 0
Study 35333095 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation (control group not explicitly mentioned)
Number of subjects: 0
Study 35333110 — intervention group
Group type: EXPERIMENTAL
Intervention: AAVhu68 delivered to the cerebrospinal fluid (CSF)
Number of subjects: 0
Study 35333110 — intervention group
Group type: EXPERIMENTAL
Intervention: AAVrh10 or AAV9 (systemic or CSF administration)
Number of subjects: 0
Study 35333135 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35333737 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib
Number of subjects: 29
Study 35333839 — intervention group
Group type: EXPERIMENTAL
Intervention: CT LUCIA 611P intraocular lens (IOL)
Number of subjects: 339
Study 35333947 — intervention group
Group type: EXPERIMENTAL
Intervention: IUGR group
Number of subjects: 54
Study 35333947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 35334038 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-VR-Onco (Core Set for Vocational Rehabilitation for Cancer Survivors)
Number of subjects: 28
Study 35334038 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-VR-Onco
Number of subjects: 28
Study 35334334 — intervention group
Group type: EXPERIMENTAL
Intervention: High Tibial Osteotomy (HTO)
Number of subjects: 4
Study 35337339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of famitinib (angiogenesis inhibitor), camrelizumab (PD-1 monoclonal antibody), and chemotherapy
Number of subjects: 48
Study 35337339 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of famitinib, camrelizumab, and chemotherapy
Number of subjects: 48
Study 35337335 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually guided target walking (TW) with handrail support
Number of subjects: 13
Study 35337335 — intervention group
Group type: COMPARATOR
Intervention: Normal treadmill walking (NW)
Number of subjects: 13
Study 35337335 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean CoM Euclidean distance TW-NW
Number of subjects: 13
Study 35337335 — intervention group
Group type: EXPERIMENTAL
Intervention: CoM trajectory length during TW
Number of subjects: 13
Study 35337365 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 0
Study 35337388 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal physical therapy program (manual therapy, therapeutic exercise, static progressive splinting) over 4 weeks
Number of subjects: 10
Study 35337388 — intervention group
Group type: COMPARATOR
Intervention: Manipulation under anesthesia followed by physical therapy
Number of subjects: 10
Study 35337614 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 1200
Study 35337614 — intervention group
Group type: COMPARATOR
Intervention: Tubal ligation or no surgery
Number of subjects: 1200
Study 35337750 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive genomic profiling (CGP) using archival tumor tissue
Number of subjects: 39
Study 35337750 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 39
Study 35337972 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib + Endocrine Therapy (ET)
Number of subjects: 5591
Study 35337972 — intervention group
Group type: COMPARATOR
Intervention: Endocrine Therapy (ET) alone
Number of subjects: 5591
Study 35338084 — intervention group
Group type: EXPERIMENTAL
Intervention: VCN-01
Number of subjects: 28
Study 35338084 — intervention group
Group type: EXPERIMENTAL
Intervention: VCN-01 + nab-paclitaxel + gemcitabine
Number of subjects: 28
Study 35338252 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal weight loss (MWL) between 5% to 15%
Number of subjects: 883
Study 35338252 — intervention group
Group type: EXPERIMENTAL
Intervention: Average total fluid administration (TFA) > 150 mL/kg birthweight/day
Number of subjects: 883
Study 35338445 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex polymerase chain reaction (PCR)
Number of subjects: 48
Study 35338773 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-specific CAR T cell-based therapy
Number of subjects: 48
Study 35339025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 400 mg BID for 14 days
Number of subjects: 20
Study 35339025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 1400 mg BID in 28-day cycles (continuously dosed)
Number of subjects: 20
Study 35339025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 20
Study 35339285 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital SBP 40 to 130 mmHg
Number of subjects: 12169
Study 35339285 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital SBP 130 to 180 mmHg
Number of subjects: 12169
Study 35339285 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital SBP above 180 mmHg
Number of subjects: 12169
Study 35339285 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmortality outcomes (hospital length of stay, ICU length of stay, discharge to skilled nursing/inpatient rehabilitation, hospital charges)
Number of subjects: 12169
Study 35339664 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index
Number of subjects: 238
Study 35339664 — intervention group
Group type: EXPERIMENTAL
Intervention: TyG index combined with GGT
Number of subjects: 238
Study 35339766 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Summer Learners (HSL)
Number of subjects: 0
Study 35339766 — intervention group
Group type: COMPARATOR
Intervention: 21st Century Summer Learning Program (21 C)
Number of subjects: 0
Study 35339766 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 35340081 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate cytoreductive nephrectomy
Number of subjects: 0
Study 35340081 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred cytoreductive nephrectomy
Number of subjects: 0
Study 35340081 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasectomy
Number of subjects: 0
Study 35340081 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapies for metastatic lesions
Number of subjects: 0
Study 35340264 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes + PFT (platin-5FU + trastuzumab)
Number of subjects: 65
Study 35340264 — intervention group
Group type: COMPARATOR
Intervention: PFT (platin-5FU + trastuzumab)
Number of subjects: 65
Study 35340685 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery or local excision at 13-16 weeks (experimental arm)
Number of subjects: 148
Study 35340685 — intervention group
Group type: COMPARATOR
Intervention: Surgery or local excision at 9-11 weeks (control arm)
Number of subjects: 148
Study 35340685 — intervention group
Group type: EXPERIMENTAL
Intervention: nCRT with a total dose of 55 Gy in 25 fractions on Gross Tumor Volume (GTV) plus 45 Gy in 25 fractions on the whole pelvis, with continuous oral capecitabine chemotherapy.
Number of subjects: 148
Study 35341327 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary and cardiac imaging (invasive or computed tomography angiography, magnetic resonance or echocardiography)
Number of subjects: 100
Study 35341327 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary and cardiac imaging
Number of subjects: 100
Study 35341327 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatments
Number of subjects: 100
Study 35341613 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication for addiction treatment (MAT)
Number of subjects: 28
Study 35341612 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training intervention
Number of subjects: 1026
Study 35341724 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial wave therapy (RW group) - 6 weekly sessions
Number of subjects: 80
Study 35341724 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (control group) - 6 weekly sessions
Number of subjects: 80
Study 35341724 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial wave therapy (RW group)
Number of subjects: 80
Study 35341724 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (control group)
Number of subjects: 80
Study 35341952 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal expulsion device (RED)
Number of subjects: 52
Study 35341952 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal RED
Number of subjects: 52
Study 35341952 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal RED (expulsion within 5 seconds or >120 seconds)
Number of subjects: 52
Study 35341952 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated RED retained >13 seconds
Number of subjects: 52
Study 35341993 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-FNA
Number of subjects: 75
Study 35342110 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection prevention protocols implemented in homes via community health workers/Promotoras.
Number of subjects: 0
Study 35342110 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSAC involvement in trial oversight and shared decision-making.
Number of subjects: 0